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theOBJECTIVES This study determined whether in vivo positron emission tomography (PET) of arterial inflammation
(18F-fluorodeoxyglucose [18F-FDG]) or microcalcification (18F-sodium fluoride [18F-NaF]) could predict restenosis
following PTA.
BACKGROUND Restenosis following lower limb percutaneous transluminal angioplasty (PTA) is common, unpredict-
able, and challenging to treat. Currently, it is impossible to predict which patient will suffer from restenosis following
angioplasty.
METHODS In this prospective observational cohort study, 50 patients with symptomatic peripheral arterial disease
underwent 18F-FDG and 18F-NaF PET/computed tomography (CT) imaging of the superficial femoral artery before and
6 weeks after angioplasty. The primary outcome was arterial restenosis at 12 months.
RESULTS Forty subjects completed the study protocol with 14 patients (35%) reaching the primary outcome of
restenosis. The baseline activities of femoral arterial inflammation (18F-FDG tissue-to-background ratio [TBR] 2.43
[interquartile range (IQR): 2.29 to 2.61] vs. 1.63 [IQR: 1.52 to 1.78]; p < 0.001) and microcalcification (18F-NaF TBR 2.61
[IQR: 2.50 to 2.77] vs. 1.69 [IQR: 1.54 to 1.77]; p < 0.001) were higher in patients who developed restenosis. The pre-
dictive value of both 18F-FDG (cut-off TBRmax value of 1.98) and 18F-NaF (cut-off TBRmax value of 2.11) uptake
demonstrated excellent discrimination in predicting 1-year restenosis (Kaplan Meier estimator, log-rank p < 0.001).
CONCLUSIONS Baseline and persistent femoral arterial inflammation and micro-calcification are associated with
restenosis following lower limb PTA. For the first time, we describe a method of identifying complex metabolically active
plaques and patients at risk of restenosis that has the potential to select patients for intervention and to serve as a
biomarker to test novel interventions to prevent restenosis. (J Am Coll Cardiol Img 2019;-:-–-) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2019.03.031
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L ower limb peripheral arterial disease(PAD) is the third leading causeof atherosclerotic cardiovascular
morbidity, following coronary artery disease
and stroke (1). PAD is a global problem,
affecting more than 200 million people
worldwide, and is present in 20% of the pop-
ulation older than the age of 75 years (2).
Although 10% of patients with PAD are
asymptomatic (2), intermittent claudication
is the most common symptom with more se-
vere limb ischemia causing rest pain, ulcera-
tion, and gangrene. Without treatment,
patients with severe limb ischemia are at
high risk of lower limb amputation.
Revascularization is the mainstay of
treatment for symptomatic lower limb PAD.
The endovascular route offers several ad-
vantages over open surgical revasculariza-
tion and is increasingly preferred.
Percutaneous transluminal angioplasty
(PTA) of the superficial femoral artery (SFA)
is the most common endovascular interven-
tion performed, but restenosis rates of 40%
to 60% at 12 months limit its long-termdurability (3,4). Arterial restenosis after PTA is a
difficult problem to solve, requiring further attempts
at revascularization with associated poorer clinical
outcomes and increased cost (5). The mechanisms
underlying vascular restenosis are complex but may
include inflammation and calcification (6). Currently,
we are unable to predict which patients will experi-
ence restenosis.
Positron emission tomography (PET) is a clinically
available molecular imaging method that produces
quantitative images of the distribution of a radio-
labelled molecule. Such images can be co-registered
with computed tomography (CT) to provide a topo-
graphical distribution of activity. 18F-Fluorodeox-
yglucose (18F-FDG), a radio-labelled glucose
analogue, is taken up by all glucose-metabolizingf England and the British Heart Foundation (BHF) (FS/16/29/31
ining fellowship (104492/Z/14/Z). Dr. Evans is supported by a fel
upported by Engineering and Physical Sciences Research Council
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England (HEFCE). Dr. Dweck is supported by the BHF (FS/14/78/
ical Research (15/JTA). Dr. Newby is supported by the BHF (CH
f a Wellcome Trust Senior Investigator Award (WT103782AIA). Dr
linical Medicine, Frank Edward Elmore Fund, and the Medical Re
(Award Reference: 1966157). Dr. Hayes has provided consultancy
lication. All other authors have reported that they have no rela
received April 10, 2019; accepted April 12, 2019.cells. 18F-FDG PET/CT is widely used in oncology to
diagnose primary and metastatic cancer. The tech-
nique has been adapted to measure arterial inflam-
mation in several vascular beds. Excessive 18F-FDG
uptake is associated with increased vascular macro-
phage burden and future cardiovascular events and is
amenable to modulation by statins, anti-
inflammatory therapies, and therapeutic lifestyle
changes.18F-Sodium fluoride (18F-NaF) is a bone PET
tracer, first introduced in 1962 for the detection of
osteogenic activity (7). More recently, 18F-NaF has
been shown to localize to developing micro-
calcifications, providing a marker of calcification ac-
tivity that has been investigated in a range of
cardiovascular disorders including aortic stenosis,
carotid and coronary atherosclerosis, and abdominal
aortic aneurysm disease (8,9).
The aim of this prospective imaging study was to
use PET/CT imaging to investigate the contribution of
inflammation (with 18F-FDG) and calcification activity
(with 18F-NaF) to the development of arterial reste-
nosis after SFA balloon angioplasty, in patients with
symptomatic PAD. PET/CT imaging was performed
before angioplasty and then repeated 6 weeks after
the procedure to assess whether either baseline or
post-procedure tracer uptake might predict those at
risk of restenosis.
METHODS
PATIENTS. Patients with symptomatic PAD who were
older than the age of 55 years were recruited from
Addenbrooke’s Hospital, Cambridge, United
Kingdom. Subjects had unilateral symptoms of either
intermittent claudication or critical limb ischemia
(CLI) and a planned SFA angioplasty (Figure 1). The
SFA lesion classification was either type A or B (based
on TransAtlantic Inter-Society Consensus II classifi-
cation system [TASC]) (10). Exclusion criteria were as
follows: renal impairment (estimated glomerular
filtration rate <30 ml/min/1.73 m2), diabetes mellitus957). Dr. Tarkin is supported by a Wellcome Trust
lowship the Dunhill Medical Trust (RTF44/0114). Dr.
(ESPRC) program grant StatScale (EP/N031938/1). Dr.
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requiring insulin therapy, a history of contrast ne-
phropathy (previously documented absolute or rela-
tive increase in serum creatinine at 48 to 72 h after
exposure to contrast agent [11]) or allergy to iodinated
contrast, presence of metastatic malignancy, inability
to provide written informed consent, inability to lie
flat during imaging, ipsilateral SFA angioplasty within
the previous 6 months, and patients undergoing
concomitant adjunct endovascular treatment (with
bare-metal or drug-eluting stents).
The baseline clinical evaluation included assess-
ment of cardiovascular risk factors, measurement of
bilateral ankle-brachial pressure indices, and clinical
biochemistry for lipid, calcium, creatinine, and high-
sensitivity C-reactive protein (hsCRP) concentrations
(Figure 1). All patients provided written informed
consent. The study was approved by the local
research ethics committee (Cambridge East Research
Ethics Committee, Reference 15/EE/0153), and was
performed in accordance with the Declaration of
Helsinki. A licence to administer radioactive medici-
nal products to consenting participants was granted
by the UK Administration of Radioactive Substances
Advisory Committee (RPC 83/400/33632). This study
is registered as ISRCTN34690731.
INDEX LESION. The index lesion was defined as the
SFA atherosclerotic lesion treated with PTA and was
defined anatomically based on previous methods
(Supplemental Figure 1) (12–14). The anatomic
boundaries of the index lesion were defined using
both the arterial duplex and CT scan at the site of
luminal stenosis and subsequent treatment. Angio-
plasty was performed in accordance with standard
practice for lower limb intervention (15). In cases of
multiple lesions (TASC B), the index lesion comprised
all segments with a luminal stenosis (as per TASC II
classification) (16), the length of which was measured
using both duplex and CT. Consequent analysis of
PET/CT, CT calcium score, and restenosis based on
duplex scanning pertains to this area, the ‘index
lesion’.
PROCEDURES. We used a combination of non-
invasive imaging techniques. Imaging data were
collected from both 18F-FDG and 18F-NaF PET/CT
scans, CT angiograms, unenhanced CT scans, and
arterial duplex images (Figure 1).
18F-FDG and 18F-NaF PET scans were performed
using validated methods (9,17) on a GE Discovery 690
combined PET/CT system (GE Healthcare, Little
Chalfont, United Kingdom). Patients underwent both
18F-FDG and 18F-NaF PET scans before PTA and these
were repeated 6 weeks after angioplasty. Each pair of
18F-FDG and 18F-NaF PET scans was acquired within7 days of each other. Images were reconstructed using
a standard clinical VUE-point FX time-of-flight algo-
rithm. Image analysis was performed on an Apple
Macintosh computer (Apple Inc., Cupertino, Califor-
nia) using an open-source DICOM viewer (version
9.0.1, OsiriX MD Imaging Software, Pixmeo, Geneva,
Switzerland). SFA 18F-FDG and 18F-NaF uptake values
were quantified, as described below. Briefly, from the
acquired raw data, the scans were reconstructed into
3-mm slices. Circular regions of interest were placed
around the SFA on adjacent axial images. The
maximum standardized uptake value (SUV) for each
identified slice was recorded. Target-to-background
ratio (TBR) was calculated by dividing the maximum
arterial SUV by blood pool activity (the mean SUV
from 5 circular regions of interest drawn in the center
of the common femoral vein). The arterial slices that
spanned the length of the index lesion were then
used to calculate the index lesion TBRmax.
The CT calcium score of the index lesion was
measured on non-contrast CT images of the SFA using
the freely available ‘Calcium Scoring’ plug-in for the
OsiriX software. The method of Agatston et al. (18),
based on an attenuation threshold of 130 Hounsfield
units in 3 contiguous voxels, was used (19). The
extent of calcification was expressed as a score in
Agatston units (AU).
The primary outcome was restenosis of the angio-
plastied index lesion, defined as a SFA stenosis
of $50% (20), measured during a repeat study arterial
duplex scan performed 12 months after angioplasty
(as part of the study protocol). The full length of the
SFA (defined anatomically) was analyzed in 4-cm
lengths in keeping with an ultrasound probe length
of 40 mm. Time to restenosis was also determined in
those patients who re-presented to the vascular sur-
gery department with symptom recurrence and a
duplex-defined restenosis before the end of the 12-
month follow-up period.
STATISTICAL ANALYSIS, REPRODUCIBILITY, AND
POWER CALCULATION. All statistical analysis was
performed using SPSS (version 25, IBM, Armonk, New
York) and The R Project for Statistical Computing
Programme (version 3.5.1, Vienna, Austria). Contin-
uous variables were expressed as mean  SD for
normally distributed data and median (interquartile
range [IQR]) for skewed distributions. Parametric
(unpaired and paired t-tests) and nonparametric
(Mann-Whitney U) tests were used for normally
distributed and skewed data, respectively. After
appropriate checks for normality, TBRmax values for
patients with and without restenosis were analysed
using the Mann-Whitney U test. Baseline correlations
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Study protocol flow stream illustrated on the left, with accompanying timeline on the right. ABPI ¼ ankle-brachial pressure index; BMI ¼ body
mass index; CIRLA ¼ Calcification and Inflammation on Restenosis rates following Lower limb Angioplasty; 18F-FDG ¼ 18F fluorodeox-
yglucose; 18F-NaF ¼ 18F-sodium fluoride; PAD ¼ peripheral arterial disease; PET/CT ¼ positron emission tomography-computed tomography;
PTA ¼ percutaneous transluminal angioplasty; SFA ¼ superficial femoral artery; TASC ¼ TransAtlantic Inter-Society Consensus.
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between 18F-FDG, 18F-NaF, and risk factors were
examined using Spearman rank correlation co-
efficients (nonparametric data). Intra-class correla-
tion coefficients were calculated to assess average
intra-observer (1-way random effects model) and
inter-observer (2-way random effects model) agree-
ment of TBRmax measurements. Kolmogorov-
Smirnoff tests were used to compare the distribu-
tion of PET tracer uptake values for patients withrestenosis to the distribution for patients without,
and Kaplan-Meier survival analyses were used to
determine restenosis probabilities. Cut-off values
were determined using R function rpart to fit classi-
fication tree data. Data are presented as n (%), mean 
SD or 95% confidence interval (CI), or median (inter-
quartile range) as appropriate. Two-sided p values
were used in all cases, with values <0.05 considered
to be significant.






(n ¼ 14) p Value
Age in yrs, 71$5 (64.8–79.3) 73.5 (67.5–80.5) 63 (60–75) 0.051
Men 26 (65%) 17 (65%) 9 (64%) 0.945
Subgroup
Intermittent claudication 31 (78%) 19 (73%) 12 (86%) 0.367
Critical limb ischemia 9 (23%) 7 (27%) 2 (14%) 0.125
TASC A 26 (65%) 19 (73%) 7 (50%) 0.243
TASC B 14 (35%) 7 (27%) 7 (50%) 0.327
Previous medical history
Hypertension 32 (80%) 19 (73%) 13 (93%) 0.141
Non-insulin dependent
diabetes
14 (35%) 9 (35%) 5 (36%) 0.945
Ischaemic heart disease/MI 15 (38%) 7 (27%) 8 (57%) 0.063
Cerebrovascular event/TIA 5 (13%) 3 (12%) 2 (14%) 0.805
Smoker 4 (10%) 3 (12%) 1 (7%) 0.663
Ex-smoker 36 (90%) 22 (85%) 13 (93%) 0.572
Medication
Clopidogrel 6 (15%) 5 (19%) 1 (7%) 0.178
Aspirin 26 (65%) 15 (58%) 11 (79%) 0.652
Anticoagulation 4 (10%) 3 (12%) 1 (7%) 0.892
Dyprimadole 1 (3%) 1 (4%) - 0.546
Statin 36 (90%) 22 (85%) 13 (93%) 0.458
ACE inhibitor 20 (50%) 13 (50%) 7 (50%) 0.982
BMI (kg/m2) 28.57  4.35 28.84  4.84 28.07  3.37 0.821
ABPI 0.72 (0.68–0.77) 0.74 (0.68–0.79) 0.70 (0.66–0.75) 0.154
Lipid profile (mmol/l)
Total cholesterol 4.38  1.05 4.40  1.08 4.33  1.04 0.777
HDL cholesterol 1.27  0.36 1.29  0.40 1.23  0.28 0.766
LDL cholesterol 2.17  0.84 2.23  0.75 2.06  1.00 0.328
Triglycerides 2.01  0.96 1.98  1.05 2.29  0.77 0.201
HDL:cholesterol 3.68  1.14 3.7  1.21 3.65  1.02 0.989
Serum calcium and creatinine
Creatinine (mmol/l) 78.5 (67.75–89.25) 78.5 (65.25–89.75) 79 (72–88.75) 0.766
Corrected calcium (mmol/l) 2.36 (2.31–2.42) 2.33 (2.31–2.42) 2.38 (2.35–2.41) 0.348
High sensitivity CRP (mg/dl) 2.77 (1.10–8.80) 3.90 (1.19–8.71) 2.1 (1.05–8.61) 0.61
Values are median (interquartile range), n (%), or mean  SD.
ABPI ¼ ankle-brachial pressure index; ACE ¼ angiotensin-converting enzyme; CRP ¼ C-reactive protein; HDL ¼
high-density lipoprotein; LDL ¼ low-density lipoprotein; MI ¼ myocardial infarction; TASC ¼ TransAtlantic Inter-
Society Consensus; TIA ¼ transient ischemic attack.
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See the Supplemental Appendix for further statis-
tical methodology.
RESULTS
A total of 86 patients were identified as eligible for
enrollment. Fifty-five patients were eligible for inclu-
sion and 50 patients agreed to participate (Supple-
mental Table 1). Ten patients did not complete the
study protocol because of the following: stenting per-
formed due to a suboptimal PTA (n ¼ 5), patient with-
drawal from the study before the 6-week scan (n ¼ 3),
and no angioplasty performed because of an unfavor-
able lesion profile at the time of angioplasty (n ¼ 2).
Subsequent results, therefore, refer to the 40 patients
who successfully completed the study protocol
(Table 1), with no baseline differences between the
restenosis and no-restenosis cohorts. Characterization
of PAD symptoms was consistent with the diagnosis of
CLI as Rutherford Grade 3, Category 5 (Table 1) (21).
The median time from angioplasty to the study exit
ultrasound scan was 371 (IQR: 365 to 385) days.
Fourteen patients experienced the primary outcome
of development of anatomic restenosis, with the
median time to identification of restenosis being 179
(IQR: 126 to 231) days.
PET IMAGING. The median time from baseline PET/
CT imaging (Central Illustration) to index lesion an-
gioplasty was 21 (IQR: 12 to 38) days. The median time
from successful angioplasty to follow-up PET/CT im-
aging was 46 (IQR: 43 to 48) days.
The overall median baseline 18F-FDG TBRmax was
1.79 (IQR: 1.60 to 2.29), with a median 6-week TBRmax
of 1.21 (IQR: 1.07 to 2.34). The median baseline
18F-NaF TBRmax was 1.78 (IQR: 1.62 to 2.50), with a
median 6-week TBRmax of 1.29 (IQR: 1.17 to 2.60). In
general, there was a 32% decrease in 18F-FDG
(p ¼ 0.034) and a 28% decrease in 18F-NaF (p ¼ 0.043)
uptake from baseline to 6 weeks after the angioplasty.
Lesion 18F-FDG and 18F-NaF uptake were highly
correlated both at baseline (r ¼ 0.818, p < 0.001) and
at 6 weeks (r ¼ 0.726, p < 0.001).
In patients who developed anatomic restenosis
within 12 months, both baseline 18F-FDG TBRmax (1.63
[IQR: 1.52 to 1.78] vs. 2.43 [IQR: 2.29 to 2.61],
p < 0.001) (Figure 2A) and 18F-NaF TBRmax (1.69 [IQR:
1.54 to 1.77] vs. 2.61 [IQR: 2.50 to 2.77], p < 0.001)
(Figure 2B) were substantially higher than those
without restenosis, and this increase persisted out to
6 weeks. In patients without restenosis, both 18F-FDG
TBRmax (1.63 [IQR: 1.52 to 1.78] vs. 1.11 [IQR: 1.03 to
1.21], p ¼ 0.034) and 18F-NaF TBRmax (1.69 [IQR: 1.55
to 1.77] vs. 1.19 [IQR: 1.10 to 1.29], p ¼ 0.047)decreased by 6 weeks. In the contralateral (untreated,
asymptomatic) limb, tracer levels for both 18F-FDG
and 18F-NaF were comparable between the two
timepoints, with no significant difference noted. The
overall median baseline 18F-FDG TBRmax was 1.35
(IQR: 1.20 to 1.70), with a median 6-week TBRmax of
1.34 (IQR: 1.19 to 1.70). The median baseline 18F-NaF
TBRmax was 1.54 (IQR: 1.36 to 1.72), with a median
6-week TBRmax of 1.55 (IQR: 1.36 to 1.71). In general,
6-week tracer levels were comparable with baseline
levels (r ¼ 0.973, p < 0.001).
CLINICAL RESTENOSIS. All patients who had
anatomic restenosis, re-presented with recurrence of
symptoms, before the 12-month duplex scan.
CENTRAL ILLUSTRATION Lower Limb 18F-NaF and 18F-FDG PET/CT Imaging
Chowdhury, M.M. et al. J Am Coll Cardiol Img. 2019;-(-):-–-.
Non-contrast CT (top left) with a rim of calcification of the vessel, 18F-NaF PET (top right), and fused 18F-NaF PET/CT (bottom left) of the
superficial femoral artery (red arrow) at the level of the adductor canal, demonstrating significant vessel uptake in patient with claudication
at 300 yards. In addition, there is prominent uptake seen in the vessel at the same level on the coronal image (bottom right). The same
plaque imaged at 6 weeks post angioplasty demonstrates dampened signal uptake (far right, red arrow), with a patient who did not develop
restenosis. Non-contrast CT (top left) with calcification of the vessel, 18F-FDG PET (top right) and fused 18F-NaF PET/CT (bottom left) of
the superficial femoral artery (blue arrow) at the level mid-thigh, demonstrating significant vessel uptake in a patient with tissue loss in the
left leg. In addition, there is prominent uptake seen across the whole vessel coronal image (bottom right), in comparison with the
contralateral leg. The same plaque imaged at 6 weeks post angioplasty demonstrates a persistent signal uptake (far right), in a patient who
did develop restenosis. CT ¼ computed tomography; 18F-FDG ¼ 18F-fluorodeoxyglucose; 18F-NaF ¼ 18F-sodium fluoride; PET ¼ positron
emission tomography.
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FIGURE 2 Comparison Between 18F-FDG and 18F-NaF Signal Stratified by Restenosis
Status at 12 Months, for Both Baseline and Post-PTA
18F-FDG: BASELINE (a) and POST-PTA (b)























































Tukey dot plots to illustrate the comparison between 18F-FDG TBRmax (A) at baseline
imaging (a) and post-PTA (b) comparing patients who suffered from restenosis (n ¼ 14,
green) and those who did not (n ¼ 26, pink). Mann-Whitney U test used for comparisons.
Dots are actual median TBRmax values per patient, bars demonstrate median þ inter-
quartile range. ** p < 0.001, * p <0.05. Tukey dot plots to illustrate the comparison
between 18F-NaF TBRmax (B) at baseline imaging (a) and post-PTA (b) comparing pa-
tients who suffered from restenosis (n ¼ 14, green) and those who did not (n ¼ 26, pink).
Mann-Whitney U test used for comparisons. Dots are actual median TBRmax values per
patient, bars demonstrate median þ interquartile range. ** p < 0.001, * p <0.05.
TBRmax ¼ target-to-background ratio maximum; other abbreviations as in Figure 1.
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Symptom recurrence included stable claudication
(n ¼ 7), worsening claudication (n ¼ 5), and worsening
pain with non-healing ulcer (n ¼ 2). In the no-
restenosis group, 4 people developed symptoms
during follow-up, which was manifest by a deterio-
ration of walking distance.
The predictive value of both 18F-FDG (with a cut-
off TBRmax value of 1.98) and 18F-NaF (with a cut-off
TBRmax value of 2.11) PET was highly discriminatory
for the occurrence of restenosis at 1 year (p < 0.0001,
log-rank p < 0.001) (Figure 3). In contrast, there was
no difference in the index lesion calcium score be-
tween those who did or did not develop restenosis
(1,143 AU [IQR: 435 to 2,144 AU] vs. 1,082 AU [IQR: 407
to 2,101 AU], respectively, p > 0.05). There was a
significant positive correlation between symptomatic
lesion 18F-NaF versus calcium score (r ¼ 0.322,
p ¼ 0.043). No significant correlation was noted
between 18F-FDG and calcium score.
DISCUSSION
In patients undergoing SFA angioplasty, we have
demonstrated for the first time that baseline arterial
inflammation and calcification activity can identify
patients who will progress to symptomatic restenosis
within a year. Moreover, symptomatic anatomic
restenosis is associated with persistent vascular
inflammation and calcification activity following PTA.
This suggests that the atherosclerotic activity of the
vascular wall determines downstream restenosis, and
that this is a target for patient selection and poten-
tially therapeutic manipulation.
This study is the first to evaluate both 18F-FDG
and 18F-NaF uptake prospectively within a symp-
tomatic PAD cohort. Interestingly, despite their
disparate effects and pathways, we found that both
tracers performed well in identifying patients who
would develop restenosis within 12 months in all
cases. Furthermore, in contrast to preceding PET
imaging studies in the coronary and carotid vascular
beds, we have demonstrated a high level of
discrimination between both 18F-FDG and 18F-NaF
arterial uptake with regard to restenosis status at 1
year, demonstrating a clear separation and no
overlap of uptake values, a finding that in itself
makes it very attractive for clinical decision-making.
Interestingly, patients who did not develop reste-
nosis demonstrated a significant decrease in tracer
activity, which perhaps suggested a positive
remodelling effect on plaque dynamics in these
patients after angioplasty (Supplemental Figure 3).
This may indicate that a subset of patients (who donot develop restenosis) observe a dampening of
inflammation at the plaque level post-angioplasty,
whereas patients who do develop restenosis do
not respond in the same manner. It is unclear
whether there is a phenotypic difference in plaque
biology, and this warrants further investigation.
Restenosis following angioplasty is a burdensome
and vexing problem, associated with poor out-
comes, including mortality. PET/CT imaging in
vascular disease is currently used as a research tool,
without a clinical translational role. Given the
increasing ease-of-access to PET imaging in many
healthcare systems, and the simplicity and low cost
of the radiotracers used, our study opens up the
possibility of routine PET imaging in patients with
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PAD prior to intervention. Indeed, the cost of a
single PET-CT examination is approximately £550 to
£800 and re-intervention costs, in addition to those
associated with the initial PTA, are £700 to £800
(22). However, a formal economic assessment of the
use of PET in this role needs to be undertaken to
determine its clinical effectiveness. This will also
require external validation studies as well as clinical
effectiveness trials where decisions to undertake
PTA will be determined by baseline PET
assessments.
In addition to guiding the initial therapeutic
approach, peripheral vascular PET would be an ideal
tool to assess the role of emerging endovascular
therapies. The role of drug-coated balloon (DCB) an-
gioplasty is not well-defined for PAD, predominately
due to high costs and lack of data in complex pop-
ulations (23). The use of PET imaging as a surrogate
biomarker to assess the efficacy of DCB may aid in
defining clear, objective validation of their use, on a
plaque-specific basis. Furthermore, other novel local
therapies including the Bullfrog Micro-Infusion
Device (Mercator MedSystems) (24) or systemic ther-
apies including PCSK9 inhibitors (25) and canakinu-
mab could be assessed in this manner.
The mechanisms associated with vascular reste-
nosis include endothelial denudation, oxidative
stress, proliferating macrophages and vascular
smooth muscle cells (26), and constrictive arterial
wall remodelling (6). Many of these processes will be
reflected in uptake of 18F-FDG and 18F-NaF. It is clearthat 18F-FDG uptake is reflective of macrophage ac-
tivity at the plaque-level, which has been implicated
in restenosis pathophysiology (27). Previous studies
have highlighted the role of calcification in reste-
nosis (28) and our findings indicate that micro-
calcification (>50 mm) is associated with high-risk
atherosclerotic plaques in both the coronary and
carotid arteries (29–31). Moreover, it provides a
marker of disease activity in other peripheral
vascular conditions, such as abdominal aortic aneu-
rysm disease, where it predicts aneurysm growth,
and the risk of surgery or rupture (32).
STUDY LIMITATIONS. Patients with diabetes on in-
sulin were excluded because elevated blood glucose
levels preclude accurate 18F-FDG uptake measure-
ments. The equivalence in performance between
18F-FDG and 18F-NaF in this study and the fact that
18F-NaF can be used in patients with diabetes
without restrictions mean that 18F-NaF may be
preferred for future studies aimed at predicting
restenosis. The study was limited to patients with
TASC A and B lesions to reduce variability and het-
erogeneity and because angioplasty is the recom-
mended treatment for these lesions. Debate
continues as to the optimal management (endovas-
cular or open surgical) of more complex lesions
(3,33). Furthermore, this study did not look at pa-
tients who underwent SFA stenting, which has an
increasing role in the lower limb. These data will
require prospective external validation, and the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Major determi-
nants in restenosis following lower limb angioplasty have been
based on systemic risk factors. To date, no independent factors
of plaque biology have the ability to identify high-risk restenosis
patients. PET with 18F-labelled FDG and NaF can provide plaque-
specific data that conventional imaging does not provide.
TRANSLATIONAL OUTLOOK 1: Detection of levels of
inflammation and microcalcification at the plaque level can allow
for identification of the high-risk plaque that may experience
restenosis after percutaneous revascularization.
TRANSLATIONAL OUTLOOK 2: Lower limb plaque imaging
using PET/CT is reproducible and feasible in many healthcare
systems and the simplicity and low cost of tracers used opens up
the possibility of routine PET imaging in patients with PAD prior
to intervention.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 9 Chowdhury et al.
- 2 0 1 9 :- –- PET/CT Identifies Restenosis in PAD Patients
9
generalizability of the current findings is limited by
the modest sample size and single-center setting.
CONCLUSIONS
Noninvasive molecular imaging using 18F-FDG and
18F-NaF PET of patients undergoing SFA angio-
plasty reliably identifies those who will develop
restenosis at 1 year. Additionally, our data suggest
that restenosis occurs because of incomplete reso-
lution of inflammation and micro-calcification after
angioplasty. Future studies are now needed to
establish whether PET can improve the manage-
ment of patients with symptomatic PAD by identi-
fying those at risk of restenosis in a larger cohort,
and to determine whether this imaging technique
might be used as a platform to test anti-restenosis
interventions.
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